VERTEX PHARMACEUTICALS INC / MA Net Cash Provided by (Used in) Operating Activities, Continuing Operations
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of $227.28 million for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2012-11-06
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) operating activities, continuing operations for the quarter ending 2012-09-30 was $105.96M, a 147.02% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) operating activities, continuing operations for the quarter ending 2012-06-30 was $118.41M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) operating activities, continuing operations for the quarter ending 2012-03-31 was $2.92M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) operating activities, continuing operations for the quarter ending 2011-12-31 was $503.66M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) operating activities, continuing operations for fiscal 2011 was $143.74M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) operating activities, continuing operations for fiscal 2010 was -$635.44M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) operating activities, continuing operations for fiscal 2009 was -$427.59M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2012-09-30 | $105.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $224.37M derived: sum of 2 quarters · filed 2012-11-06 | $227.28M 10-Q · filed 2012-11-06 | $730.95M derived: sum of 4 quarters · filed 2012-11-06 |
| 2012-06-30 | $118.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $121.32M 10-Q · filed 2012-08-08 | $624.98M derived: sum of 3 quarters · filed 2012-08-08 | $667.88M derived: sum of 4 quarters · filed 2012-11-06 |
| 2012-03-31 | $2.92M 10-Q · filed 2012-05-10 | $506.58M derived: sum of 2 quarters · filed 2012-05-10 | $549.47M derived: sum of 3 quarters · filed 2012-11-06 | $333.28M derived: sum of 4 quarters · filed 2012-11-06 |
| 2011-12-31 | $503.66M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $546.56M derived: sum of 2 quarters · filed 2012-11-06 | $330.36M derived: sum of 3 quarters · filed 2012-11-06 | $143.74M 10-K · filed 2012-02-22 |
| 2011-09-30 | $42.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$173.30M derived: sum of 2 quarters · filed 2012-11-06 | -$359.93M 10-Q · filed 2012-11-06 | -$526.03M derived: sum of 4 quarters · filed 2012-11-06 |
| 2011-06-30 | -$216.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$402.82M 10-Q · filed 2012-08-08 | -$568.93M derived: sum of 3 quarters · filed 2012-08-08 | |
| 2011-03-31 | -$186.63M 10-Q · filed 2012-05-10 | -$352.73M derived: sum of 2 quarters · filed 2012-05-10 | ||
| 2010-12-31 | -$166.10M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$635.44M 10-K · filed 2012-02-22 | ||
| 2010-09-30 | -$469.34M 10-Q · filed 2011-11-03 | |||
| 2009-12-31 | -$427.59M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |